Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects

References

• Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet345(8964), 1545–1548 (1995).
   PubMed Web of Science ®Google Scholar
• Grange JM. DOTS and beyond: towards a holistic approach to the conquest of tuberculosis. Int. J. Tuberc. Lung Dis.1(4), 293–296 (1997).
   PubMedGoogle Scholar
• Iseman MD. MDR-TB and the developing world – a problem no longer to be ignored: the WHO announces ‘DOTS-Plus’ strategy. Int. J. Tuberc. Lung Dis.2(11), 867 (1998).
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Stop TB Strategy: Building on and Enhancing DOTS to Meet the TB-Related Millenium Development Goals. WHO/HTM/TB/2006.368 (2006).
   Google Scholar
• Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000–2004. Morb. Mortal. Wkly Rep.55(11), 301–305 (2006).
   PubMedGoogle Scholar
• Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet368(9547), 1575–1580 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Global MDR-TB & XDR-TB Response Plan 2007–2008. WHO/HTM/TB/2007.387 (2007).
   Google Scholar
• World Health Organization. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411 (2009).
   Google Scholar
• World Health Organization. WHO/HTM/TB/2008.394. Anti-tuberculosis Drug Resistance in the World. Report No. 4 (2008).
   Google Scholar
• Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis.45(11), 1409–1414 (2007).
   PubMed Web of Science ®Google Scholar
• Jeon CY, Hwang SH, Min JH et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis.46(1), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Wang JY, Hsueh PR, Jan IS et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax61(10), 903–908 (2006).
   PubMed Web of Science ®Google Scholar
• Chiang CY, Enarson DA, Fujiwara PI, Van Deun A, Lee JJ. Strategies of extensively drug-resistant TB risk management for health workers and other care givers. Expert Rev. Resp. Med.2, 47–54 (2008).
   PubMedGoogle Scholar
• Sullivan EA, Kreiswirth BN, Palumbo L et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet345(8958), 1148–1150 (1995).
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Hooper N, Parrish N et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis.37(11), 1448–1452 (2003).
   PubMed Web of Science ®Google Scholar
• Grimaldo ER, Tupasi TE, Rivera AB et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis.5(6), 546–550 (2001).
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Woolwine SC, Hooper N et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med.349(20), 1977–1978 (2003).
   PubMedGoogle Scholar
• Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis.21(6), 587–595 (2008).
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J.33(4), 871–881 (2009).
   PubMed Web of Science ®Google Scholar
• Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect. Dis.7(7), 443 (2007).
   PubMed Web of Science ®Google Scholar
• Farmer P, Kim JY. Community based approaches to the control of multidrug-resistant tuberculosis: introducing ‘DOTS-plus’. BMJ317(7159), 671–674 (1998).
   PubMed Web of Science ®Google Scholar
• Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug-resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ326(7389), 574 (2003).
   PubMedGoogle Scholar
• Salomon JA, Lloyd-Smith JO, Getz WM et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med.3(8), E273 (2006).
   PubMedGoogle Scholar
• Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug-resistant tuberculosis in Europe: a systematic review. Thorax61(2), 158–163 (2006).
   PubMed Web of Science ®Google Scholar
• Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: update 2007. Respirology13(1), 21–46 (2008).
   PubMed Web of Science ®Google Scholar
• French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V, Abubakar I. The association between HIV and antituberculosis drug resistance. Eur. Respir. J.32(3), 718–725 (2008).
   PubMedGoogle Scholar
• Chang KC, Yew WW, Zhang Y. A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opin. Med. Diag.3(2), 99–122 (2009).
   PubMedGoogle Scholar
• O’Riordan P, Schwab U, Logan S et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multidrug-resistant tuberculosis: case control study. PLoS ONE3(9), E3173 (2008).
   Google Scholar
• Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med.177(7), 787–792 (2008).
   PubMed Web of Science ®Google Scholar
• Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 46–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis.3(10), S231–S279 (1999).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis – Emergency Update 2008. WHO/HTM/TB/2008.402. (2008).
   Google Scholar
• Cegielski P. Treatment of MDR-TB: are observational studies key to solving programmatic issues? Int. J. Tuberc. Lung Dis.12(11), S47–S48 (2008).
   Google Scholar
• Dalton T, Leimane V, Kurbatova E et al. Prevalence of second-line drug resistance among MDR-TB patients in 7 countries in the PETTS Study. Int. J. Tuberc. Lung Dis.12(11), S162 (2008).
   Google Scholar
• Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis.12(8), 869–877 (2008).
   PubMed Web of Science ®Google Scholar
• Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis.9(3), 153–161 (2009).
   PubMed Web of Science ®Google Scholar
• Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med.169(10), 1103–1109 (2004).
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Girardi E et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J.31(4), 904–905 (2008).
   PubMed Web of Science ®Google Scholar
• Devasia RA, Blackman A, May C et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS, and nitrate reductase assay and fluoroquinolone cross-resistance. J. Antimicrob. Chemother.63(6), 1173–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs67(14), 2077–2099 (2007).
   PubMed Web of Science ®Google Scholar
• Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest124(4), 1476–1481 (2003).
   PubMedGoogle Scholar
• Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis.190(9), 1642–1651 (2004).
   PubMed Web of Science ®Google Scholar
• Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int. J. Tuberc. Lung Dis.11(6), 606–611 (2007).
   PubMed Web of Science ®Google Scholar
• Yew WW, Chau CH, Wen KH. Linezolid in the treatment of ‘difficult’ multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.12(3), 345–346 (2008).
   PubMedGoogle Scholar
• Dietze R, Hadad DJ, McGee B et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.178(11), 1180–1185 (2008).
   PubMed Web of Science ®Google Scholar
• Nam HS, Koh WJ, Kwon OJ. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis (letter). Int. J. Antimicrob. Agents33(1), 92–93 (2009).
   PubMedGoogle Scholar
• Shim TS, Lim J, Gwak H et al. Efficacy and tolerability of a daily dose of 300 mg linezolid in patients with intractable MDR- and XDR-TB. Int. J. Tuberc. Lung Dis.12(11), S203 (2008).
   Google Scholar
• Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin. Pharmacother.10(3), 381–401 (2009).
   PubMed Web of Science ®Google Scholar
• Williams KN, Stover CK, Zhu T et al. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob. Agents Chemother.53(4), 1314–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis.33, 466–469 (2001).
   PubMed Web of Science ®Google Scholar
• Abate G, Miorner H. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxicillin in combination with clavulanic acid and ethambutol. J. Antimicrob. Chemother.42, 735–740 (1998).
   PubMed Web of Science ®Google Scholar
• Dincer I, Ergin A, Kocagoz T. The in vitro efficacy of b-lactam and β-lactamase inhibitors against multidrug-resistant clinical strains of Mycobacterium tuberculosis. Int. J. Antimicrob. Agents23, 408–411 (2004).
   PubMed Web of Science ®Google Scholar
• Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberclosis. Chest99, 1025–1026 (1991).
   PubMed Web of Science ®Google Scholar
• Yew WW, Wong CF, Lee J, Wong PC, Chau CH. Do b-lactam–β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuberc. Lung Dis.76, 90–92 (1995).
   PubMedGoogle Scholar
• Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry46(43), 11998–12004 (2007).
   PubMed Web of Science ®Google Scholar
• Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother.49(7), 2816–2821 (2005).
   PubMed Web of Science ®Google Scholar
• Jagannath C, Reddy MV, Kailasam S, O’Sullivan JF, Gangadharam PR. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular and in vivo studies. Am. J. Respir. Crit. Care Med.151, 1083–1086 (1995).
   PubMed Web of Science ®Google Scholar
• Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J. Antimicrob. Chemother.47, 199–202 (2001).
   PubMedGoogle Scholar
• Janulionis E, Sofer C, Song HY, Wallis RS. Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture. Antimicrob. Agents Chemother.48, 3133–3135 (2004).
   PubMedGoogle Scholar
• Uskudar O, Koksal D, Koksul AS. Partial intestinal obstruction due to clofazimine in a patient with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.9, 703–704 (2005).
   PubMedGoogle Scholar
• Schaaf HS, Victor TC, Engelke E et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur. J. Clin. Microbiol. Infect. Dis.26(3), 203–205 (2007).
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.12(2), 139–145 (2008).
   PubMed Web of Science ®Google Scholar
• Mitnick CD, Shin SS, Seung KJ et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med.359(6), 563–574 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother.48(2), 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.10(6), 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomised trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med.4(11), E292 (2007).
   PubMed Web of Science ®Google Scholar
• Ma Z. Overview of the global TB drug pipeline. Int. J. Tuberc. Lung Dis.12(11), S13 (2008).
   PubMedGoogle Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med.354(13), 1352–1361 (2006).
   PubMed Web of Science ®Google Scholar
• Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis.196(Supp 1). S28–S34 (2007).
   PubMedGoogle Scholar
• Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother.46(6), 1875–1879 (2002).
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med.169(3), 421–426 (2004).
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med.170(10), 1131–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Gosling RD, Uiso LO, Sam NE et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168(11), 1342–1345 (2003).
   PubMed Web of Science ®Google Scholar
• Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother.48(3), 780–782 (2004).
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J. Antimicrob. Chemother.56(6), 1169 (2005).
   PubMedGoogle Scholar
• Burman WJ, Goldberg S, Johnson JL et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.174(3), 331–338 (2006).
   PubMed Web of Science ®Google Scholar
• Conde MB, Efron A, Loredo C et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled Phase II trial. Lancet373(9670), 1183–1189 (2009).
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T et al. A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.12(2), 128–138 (2008).
   PubMed Web of Science ®Google Scholar
• Dorman S, Johnson J, Goldsberg S et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Dooley K, Flexner C, Hackman J et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concenrations. Antimicrob. Agents Chemother.52(11), 4037–4042 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med.178(9), 989–993 (2008).
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science307(5707), 223–227 (2005).
   PubMed Web of Science ®Google Scholar
• Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al. Selectivity of TMC-207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother.53(3), 1290–1292 (2009).
   PubMed Web of Science ®Google Scholar
• Koul A, Vranckx L, Dendouga N et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem.283(37), 25273–25280 (2008).
   PubMed Web of Science ®Google Scholar
• Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother.52(10), 3568–3572 (2008).
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Andries K, Lounis N et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother.51(3), 1011–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Veziris N, Ibrahim M, Lounis N et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med.179(1), 75–79 (2009).
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Mitchison DA. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am. J. Respir. Crit. Care Med.179(1), 2–3 (2009).
   PubMedGoogle Scholar
• Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother.50(11), 3543–3547 (2006).
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC-207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother.52(8), 2831–2835 (2008).
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med.3(11), E466 (2006).
   PubMed Web of Science ®Google Scholar
• Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J. Antimicrob. Chemother.60(5), 994–998 (2007).
   PubMed Web of Science ®Google Scholar
• Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature405(6789), 962–966 (2000).
   PubMed Web of Science ®Google Scholar
• Singh R, Manjunatha U, Boshoff HI et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science322(5906), 1337–1338 (2008).
   PubMedGoogle Scholar
• Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother.49(6), 2289–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Rosenthal I, Tyagi S et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother.50(8), 2621–2625 (2006).
   PubMed Web of Science ®Google Scholar
• Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother.52(10), 3664–3668 (2008).
   PubMedGoogle Scholar
• Nuermberger E, Tyagi S, Tasneen R et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother.52(4), 1522–1524 (2008).
   PubMed Web of Science ®Google Scholar
• Diacon A, Dawson R, Venter A et al. Update on PA-824. Int. J. Tuberc. Lung Dis.12(11), S14 (2008).
   Google Scholar
• Hu Y, Coates AR, Mitchison DA. Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis.12(1), 69–73 (2008).
   PubMed Web of Science ®Google Scholar
• Sung JC, Carcia-Contreras L, Verberkmoes JL et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother.53(4), 1338–1343 (2009).
   PubMed Web of Science ®Google Scholar
• Deidda D, Lampis G, Fioravanti R et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother.42(11), 3035–3037 (1998).
   PubMed Web of Science ®Google Scholar
• Sinha RK, Arora SK, Sinha N, Modak VM. In vivo activity of LL-3858 against Mycobacterium tuberculosis. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November 2004 (Abstract F-1116).
   Google Scholar
• Arora SK, Anuradha K, Avhad AJ. Phase I clinical trial of LL-3858 (Sudoterb), a potential candidate for the treatment of MDR tuberculosis. Int. J. Tuberc. Lung Dis.2(11), S319–S320 (2008).
   Google Scholar
• Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ-109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother.58(2), 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis: improved outcome by combining SQ-109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother.51(4), 1563–1565 (2007).
   PubMed Web of Science ®Google Scholar
• Hurdle JG, Lee RB, Budha NR et al. A microbiological assessment of novel nitrofuranylamides as antituberculosis agents. J. Antimicrob. Chemother.62(5), 1037–1045 (2008).
   PubMed Web of Science ®Google Scholar
• Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science323(5918), 1215–1218 (2009).
   PubMed Web of Science ®Google Scholar
• Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Respir. Dis.141(3), 623–625 (1990).
   PubMed Web of Science ®Google Scholar
• Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multidrug-resistant tuberculosis. Curr. Opin. Pulm. Med.12(3), 179–185 (2006).
   PubMedGoogle Scholar
• Törün T, Tahaoglu K, Ozmen I et al. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.11(9), 979–985 (2007).
   PubMedGoogle Scholar
• Kim HJ, Kang CH, Kim YT et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur. Respir. J.28(3), 576–580 (2006).
   PubMed Web of Science ®Google Scholar
• Kwon YS, Kim YH, Suh GY et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis.47(4), 496–502 (2008).
   PubMed Web of Science ®Google Scholar
• Wu MH, Chang JM, Haung TM et al. Computed tomographic assessment of the surgical risks associated with fibrocavernous pulmonary tuberculosis. Surg. Today34(3), 204–208 (2004).
   PubMedGoogle Scholar
• Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg.128(4), 523–528 (2004).
   PubMed Web of Science ®Google Scholar
• Takeda S, Maeda H, Hayakawa M, Sawabata N, Maekura R. Current surgical intervention for pulmonary tuberculosis. Ann. Thorac. Surg.79(3), 959–963 (2005).
   PubMed Web of Science ®Google Scholar
• Park SK, Kim JH, Kang H, Cho JS, Smego RA Jr. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int. J. Infect. Dis.13(2), 170–175 (2009).
   PubMedGoogle Scholar
• Shiraishi Y, Katsuragi N, Kita H, Toishi M, Onda T. Experience with pulmonary resection for extensively drug-resistant tuberculosis. Interact. Cardiovasc. Thorac. Surg.7(6), 1075–1078 (2008).
   PubMedGoogle Scholar
• Naidoo R. Surgery for pulmonary tuberculosis. Curr. Opin. Pulm. Med.14(3), 254–259 (2008).
   PubMedGoogle Scholar
• Wang H, Lin H, Jiang G. Pulmonary resection in the treatment of multidrug-resistant tuberculosis: a retrospective study of 56 cases. Ann. Thorac. Surg.86(5), 1640–1645 (2008).
   PubMed Web of Science ®Google Scholar
• Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg.121(3), 448–453 (2001).
   PubMed Web of Science ®Google Scholar
• Deschamps C, Bernard A, Nichols FC et al. Empyema and bronchopleural fistula after pneumonectomy: factors affecting incidence. Ann. Thorac. Surg.72(1), 243–248 (2001).
   PubMedGoogle Scholar
• Motus IY, Skorniakov SN, Sokolov VA et al. Reviving an old idea: can artificial pneumothorax play a role in the modern management of tuberculosis? Int. J. Tuberc. Lung Dis.10(5), 561–567 (2006).
   Google Scholar
• Dewan RK, Singh S, Kumar A, Meena BK. Thoracoplasty: an obsolete procedure? Indian J. Chest Dis. Allied Sci.41(2), 83–88 (1999).
   PubMedGoogle Scholar
• Jouveshomme S, Dautzenberg B, Bakdach H, Derenne JP. Preliminary results of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobacteria. Am. J. Respir. Crit. Care Med.157(5 Pt 1), 1609–1615 (1998).
   PubMedGoogle Scholar
• Bertin F, Labrousse L, Gazaille V, Vincent F, Guerlin A, Laskar M. New modality of collapse therapy for pulmonary TB sequels: tissue expander. Ann. Thorac. Surg.84(3), 1023–1025 (2007).
   PubMedGoogle Scholar
• Pezzella AT, Fang W. Surgical aspects of thoracic tuberculosis: a contemporary review – part 2. Curr. Probl. Surg.45(11), 771–829 (2008).
   PubMedGoogle Scholar
• Kerti CA, Miron I, Cozma GV et al. The role of surgery in the management of pleuropulmonary tuberculosis – seven years’ experience at a single institution. Interact. Cardiovasc. Thorac. Surg.8(3), 337–338 (2009).
   PubMedGoogle Scholar
• Reljic R, Paul MJ, Arias MA. Cytokine therapy of tuberculosis at the crossroads. Expert Rev. Resp. Med.3(1), 53–66 (2009).
   PubMedGoogle Scholar
• Achkar JM, Casadevall A, Glatman-Freedman A. Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches. Expert Rev. Anti Infect. Ther.5(3), 461–474 (2007).
   PubMed Web of Science ®Google Scholar
• Suárez-Méndez R, García-García I, Fernández-Olivera N et al. Adjuvant interferon g in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis.4, 44 (2004).
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kwon OJ, Suh GY et al. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci.19(2), 167–171 (2004).
   PubMed Web of Science ®Google Scholar
• Giosuè S, Casarini M, Ameglio F et al. Aerosolized interferon-a treatment in patients with multidrug-resistant pulmonary tuberculosis. Eur. Cytokine Netw.11(1), 99–104 (2000).
   PubMed Web of Science ®Google Scholar
• Kuchtey J, Fulton SA, Reba SM, Harding CV, Boom WH. Interferon-ab mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette–Guerin infection. Immunology118(1), 39–49 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Ssekasanvu E, Okwera A et al. Randomised trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.168(2), 185–191 (2003).
   PubMed Web of Science ®Google Scholar
• Ha SJ, Park SH, Kim HJ et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. Infect. Immun.74(8), 4954–4959 (2006).
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet349(9064), 1513–1515 (1997).
   PubMed Web of Science ®Google Scholar
• Stanford JL, Stanford CA, Grange JM, Lan NN, Etemadi A. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multidrug-resistant pulmonary tuberculosis? Respir. Med.95(6), 444–447 (2001).
   PubMedGoogle Scholar
• Park SK, Cho S, Lee IH et al. Subcutaneously administered interferon-γ for the treatment of multidrug-resistant pulmonary tuberculosis. Int. J. Infect. Dis.11(5), 434–440 (2007).
   PubMedGoogle Scholar
• Grahmann PR, Braun RK. A new protocol for multiple inhalation of IFN-γ successfully treats MDR-TB: a case study. Int. J. Tuberc. Lung Dis.12(6), 636–644 (2008).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood90(7), 2541–2548 (1997).
   PubMed Web of Science ®Google Scholar
• Williams A, Reljic R, Naylor I et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology11(3), 328–333 (2004).
   Google Scholar
• Guirado E, Amat I, Gil O et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect.8(5), 1252–1259 (2006).
   PubMed Web of Science ®Google Scholar
• Wejse C, Gomes VF, Rabna P et al. Vitamin D as supplementary treatment for tuberculosis – a double-blind randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med.179(9), 843–850 (2009).
   PubMed Web of Science ®Google Scholar
• Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell119(6), 753–766 (2004).
   PubMed Web of Science ®Google Scholar
• Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Hungtington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy3(6), 620–622 (2007).
   PubMed Web of Science ®Google Scholar
• Yew WW, Chau CH. Utility of fluoroquinolones in multidrug-resistant tuberculosis – a balanced view? Int. J. Tuberc. Lung Dis.6(2), 174–175 (2002).
   PubMedGoogle Scholar
• Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/ levofloxacin-containing regimens. Chest117(3), 744–751 (2000).
   PubMed Web of Science ®Google Scholar
• Park SK, Lee WC, Lee DH et al. Self-administered standardised regimens for multidrug-resistant tuberculosis in South Korea. Int. J. Tuberc. Lung Dis.8(3), 361–368 (2004).
   PubMedGoogle Scholar
• Leimane V, Riekstina V, Holtz TH et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet365(9456), 318–326 (2005).
   PubMed Web of Science ®Google Scholar
• Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995–2003. J. Antimicrob. Chemother.56(6), 1058–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Park IN, Hong SB, Oh YM et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int. J. Tuberc. Lung Dis.11(3), 319–324 (2007).
   PubMedGoogle Scholar
• Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother.51(12), 4261–4266 (2007).
   PubMedGoogle Scholar
• Long R, Chong H, Hoeppner V et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin. Infect. Dis.48(10), 1361–1363 (2009).
   PubMedGoogle Scholar
• Mukherjee JS, Rich ML, Socci AR et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet363(9407), 474–481 (2004).
   PubMed Web of Science ®Google Scholar
• Glickman SW, Rasiel E, Hamilton CD, Kubataev A, Schulman KA. A portfolio model of drug development for tuberculosis. Science311(5765), 246–247 (2006).
   Google Scholar
• Murphy DJ, Brown JR. Novel drug target strategies against Mycobacterium tuberculosis. Curr. Opin. Microbiol.11(5), 422–427 (2008).
   PubMedGoogle Scholar
• Burman W, McNeeley D, Moulton LH, Spigelman M, Vernon A. Advancing the science in clinical trials for new TB drugs. Int. J. Tuberc. Lung Dis.12(2), 111–112 (2008).
   PubMedGoogle Scholar
• Ralph A, Kelly PM, Anstey NM. Nutritional supplements as immune-modulators to improve TB treatment outcomes. Int. J. Tuberc. Lung Dis.12(11), S14–S15 (2008).
   Google Scholar
• Villamor E, Mugusi F, Urassa W et al. A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J. Infect. Dis.197(11), 1499–1505 (2008).
   PubMed Web of Science ®Google Scholar
• Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst. Rev.4, CD006086 (2008).
   Google Scholar
• Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature393(6685), 537–544 (1998).
   PubMed Web of Science ®Google Scholar